Published in Am J Hum Genet on May 22, 2003
The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol (2010) 5.04
Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res (2008) 4.02
Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell (2011) 3.00
BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dubé syndrome: a new series of 50 families and a review of published reports. J Med Genet (2008) 2.79
LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol Cancer Ther (2009) 2.43
The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels. Cancer Cell (2011) 2.12
UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. Cancer Genet Cytogenet (2010) 2.06
Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. J Med Genet (2005) 1.85
Molecular diagnosis and therapy of kidney cancer. Annu Rev Med (2010) 1.82
Increased risk of cancer in patients with fumarate hydratase germline mutation. J Med Genet (2005) 1.61
State of the science: an update on renal cell carcinoma. Mol Cancer Res (2012) 1.58
Structural basis of fumarate hydratase deficiency. J Inherit Metab Dis (2011) 1.58
Revisiting the TCA cycle: signaling to tumor formation. Trends Mol Med (2011) 1.51
Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics. Genome Res (2012) 1.49
Renal cell carcinoma. BMJ (2014) 1.45
Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. J Urol (2012) 1.45
Molecular pathways: Fumarate hydratase-deficient kidney cancer--targeting the Warburg effect in cancer. Clin Cancer Res (2013) 1.34
Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies. Oncologist (2012) 1.33
Epidemiology of myomas. Obstet Gynecol Clin North Am (2006) 1.33
Hereditary kidney cancer: unique opportunity for disease-based therapy. Cancer (2009) 1.32
Hereditary leiomyomatosis and renal cell cancer: update on clinical and molecular characteristics. Fam Cancer (2011) 1.30
HIF and fumarate hydratase in renal cancer. Br J Cancer (2007) 1.27
Metabolic reprogramming for producing energy and reducing power in fumarate hydratase null cells from hereditary leiomyomatosis renal cell carcinoma. PLoS One (2013) 1.12
Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment. Fam Cancer (2014) 1.09
The metabolic basis of kidney cancer. Semin Cancer Biol (2012) 1.09
Missense mutations in fumarate hydratase in multiple cutaneous and uterine leiomyomatosis and renal cell cancer. J Mol Diagn (2005) 1.07
A genome-wide map of human genetic interactions inferred from radiation hybrid genotypes. Genome Res (2010) 1.07
Fumarate hydratase enzyme activity in lymphoblastoid cells and fibroblasts of individuals in families with hereditary leiomyomatosis and renal cell cancer. J Med Genet (2006) 1.07
Morphologic and molecular characteristics of uterine leiomyomas in hereditary leiomyomatosis and renal cancer (HLRCC) syndrome. Am J Surg Pathol (2013) 1.04
The clinical implications of the genetics of renal cell carcinoma. Urol Oncol (2009) 1.03
Reed's Syndrome: A Case of Multiple Cutaneous and Uterine Leiomyomas. J Clin Aesthet Dermatol (2011) 1.02
Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry. Am J Surg Pathol (2014) 1.01
Hereditary leiomyomatosis and renal cell carcinoma. Int J Nephrol Renovasc Dis (2014) 0.99
Exploring a glycolytic inhibitor for the treatment of an FH-deficient type-2 papillary RCC. Nat Rev Urol (2011) 0.98
Proceedings from the Third National Institutes of Health International Congress on Advances in Uterine Leiomyoma Research: comprehensive review, conference summary and future recommendations. Hum Reprod Update (2014) 0.98
Inter and intratumour heterogeneity: a barrier to individualized medical therapy in renal cell carcinoma? Front Oncol (2012) 0.97
A novel fumarate hydratase-deficient HLRCC kidney cancer cell line, UOK268: a model of the Warburg effect in cancer. Cancer Genet (2012) 0.96
Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy. Expert Opin Biol Ther (2008) 0.96
Racial difference in histologic subtype of renal cell carcinoma. Cancer Med (2013) 0.96
Targeting the Met signaling pathway in renal cancer. Expert Rev Anticancer Ther (2009) 0.96
The role of angiogenic factors in fibroid pathogenesis: potential implications for future therapy. Hum Reprod Update (2013) 0.93
Association of germline mutations in the fumarate hydratase gene and uterine fibroids in women with hereditary leiomyomatosis and renal cell cancer. Arch Dermatol (2008) 0.93
Familial renal cancer as an indicator of hereditary leiomyomatosis and renal cell cancer syndrome. Fam Cancer (2012) 0.93
Leiomyomata uteri: hormonal and molecular determinants of growth. J Natl Med Assoc (2007) 0.90
Cutaneous leiomyosarcoma arising in a smallpox scar. World J Surg Oncol (2012) 0.89
Circulating biomarkers in advanced renal cell carcinoma: clinical applications. Curr Oncol Rep (2012) 0.89
Non-clear cell renal cancer: disease-based management and opportunities for targeted therapeutic approaches. Semin Oncol (2013) 0.89
Review of renal cell carcinoma and its common subtypes in radiology. World J Radiol (2016) 0.89
Mapping cancer cell metabolism with(13)C flux analysis: Recent progress and future challenges. J Carcinog (2013) 0.88
Multiple cutaneous and uterine leiomyomatosis syndrome: a review. J Clin Aesthet Dermatol (2013) 0.87
Fumarate Hydratase-deficient Uterine Leiomyomas Occur in Both the Syndromic and Sporadic Settings. Am J Surg Pathol (2016) 0.86
Uterine smooth muscle tumors with features suggesting fumarate hydratase aberration: detailed morphologic analysis and correlation with S-(2-succino)-cysteine immunohistochemistry. Mod Pathol (2013) 0.85
Surgical Methods for the Treatment of Uterine Fibroids - Risk of Uterine Sarcoma and Problems of Morcellation: Position Paper of the DGGG. Geburtshilfe Frauenheilkd (2015) 0.84
10 rare tumors that warrant a genetics referral. Fam Cancer (2013) 0.84
Rare and unusual endocrine cancer syndromes with mutated genes. Semin Oncol (2010) 0.84
Dual mode action of mangiferin in mouse liver under high fat diet. PLoS One (2014) 0.83
Renal cell carcinoma: Evolving and emerging subtypes. World J Clin Cases (2013) 0.83
Hereditary leiomyomatosis and renal cell carcinoma (HLRCC): a rapid autopsy report of metastatic renal cell carcinoma. Am J Surg Pathol (2014) 0.83
Changes in mitochondrial DNA alter expression of nuclear encoded genes associated with tumorigenesis. Exp Cell Res (2012) 0.83
Genetic testing for hereditary cancer predisposition: BRCA1/2, Lynch syndrome, and beyond. Gynecol Oncol (2016) 0.83
Genetic basis of bilateral renal cancer: implications for evaluation and management. J Clin Oncol (2009) 0.83
Preoperative Evaluation of Renal Cell Carcinoma by Using 18F-FDG PET/CT. Clin Nucl Med (2015) 0.82
Hereditary kidney cancer syndromes. Adv Chronic Kidney Dis (2014) 0.82
Protein profiling of blood samples from patients with hereditary leiomyomatosis and renal cell cancer by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Int J Mol Sci (2012) 0.81
Molecular genetics and immunohistochemistry characterization of uncommon and recently described renal cell carcinomas. Chin J Cancer Res (2016) 0.81
Somatic alterations in mitochondrial DNA produce changes in cell growth and metabolism supporting a tumorigenic phenotype. Biochim Biophys Acta (2011) 0.80
Genetic testing of leiomyoma tissue in women younger than 30 years old might provide an effective screening approach for the hereditary leiomyomatosis and renal cell cancer syndrome (HLRCC). Virchows Arch (2015) 0.79
Effect of a selective progesterone receptor modulator on induction of apoptosis in uterine fibroids in vivo. Int J Endocrinol (2012) 0.78
Insights into the Genetic Basis of the Renal Cell Carcinomas from The Cancer Genome Atlas. Mol Cancer Res (2016) 0.78
Hereditary papillary renal cell carcinoma primarily diagnosed in a cervical lymph node: a case report of a 30-year-old woman with multiple metastases. BMC Urol (2013) 0.78
Current understanding of the molecular mechanisms of kidney cancer: a primer for urologists. Can Urol Assoc J (2007) 0.78
Combining differential expression, chromosomal and pathway analyses for the molecular characterization of renal cell carcinoma. Can Urol Assoc J (2007) 0.78
A critical assessment of morcellation and its impact on gynecologic surgery and the limitations of the existing literature. Am J Obstet Gynecol (2015) 0.78
Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity. EPMA J (2011) 0.76
Hereditary renal cell carcinoma: genetics, clinical features, and surgical considerations. World J Urol (2014) 0.76
Familial renal cancer: molecular genetics and surgical management. Int J Surg Oncol (2011) 0.76
A Case of Reed's Syndrome: An Underdiagnosed Tumor Disorder. Case Rep Dermatol (2014) 0.75
Melanoma and basal cell carcinoma in the hereditary leiomyomatosis and renal cell cancer syndrome. An expansion of the oncologic spectrum. J Dermatol Case Rep (2016) 0.75
Familial syndromes coupling with small renal masses. Adv Urol (2008) 0.75
Immunohistochemical Characterization of Fumarate Hydratase (FH) and Succinate Dehydrogenase (SDH) in Cutaneous Leiomyomas for Detection of Familial Cancer Syndromes. Am J Surg Pathol (2017) 0.75
Genetic counseling in renal masses. Adv Urol (2008) 0.75
Rare Leiomyoma of the Tunica Dartos: A Case Report with Clinical Relevance for Malignant Transformation and HLRCC. Case Rep Pathol (2016) 0.75
Reed syndrome presenting with leiomyosarcoma. JAAD Case Rep (2015) 0.75
Syndrome-Associated Tumors by Organ System. J Pediatr Genet (2016) 0.75
Genetic predisposition to kidney cancer. Semin Oncol (2016) 0.75
Concurrent renal-cell carcinoma and cutaneous leiomyomas: A case of HLRCC. Radiol Case Rep (2015) 0.75
Human Metabolic Enzymes Deficiency: A Genetic Mutation Based Approach. Scientifica (Cairo) (2016) 0.75
A Case of Hereditary Leiomyomatosis and Renal Cell Carcinoma. Case Rep Dermatol Med (2016) 0.75
Genetic and Chromosomal Aberrations and Their Clinical Significance in Renal Neoplasms. Biomed Res Int (2015) 0.75
Endocrine-disrupting chemicals and uterine fibroids. Fertil Steril (2016) 0.75
Renal cancer subtypes: Should we be lumping or splitting for therapeutic decision making? Cancer (2016) 0.75
Incidental diagnosis of HLRCC following investigation for Asperger Syndrome: actionable and actioned. Fam Cancer (2016) 0.75
Hereditary leiomyomatosis and renal cell cancer syndrome: identification and clinical characterization of a novel mutation in the FH gene in a Colombian family. Fam Cancer (2017) 0.75
Cascade Fumarate Hydratase mutation screening allows early detection of kidney tumour: a case report. BMC Med Genet (2017) 0.75
BLAT--the BLAST-like alignment tool. Genome Res (2002) 126.78
Strategies for multilocus linkage analysis in humans. Proc Natl Acad Sci U S A (1984) 48.41
Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites. Protein Eng (1997) 38.38
BLAST 2 Sequences, a new tool for comparing protein and nucleotide sequences. FEMS Microbiol Lett (1999) 25.40
Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet (2002) 8.19
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet (1997) 6.83
Uterine fibroids. Lancet (2001) 6.54
The Heidelberg classification of renal cell tumours. J Pathol (1997) 5.36
Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol (1997) 4.84
Hysterectomy rates in the United States 1990-1997. Obstet Gynecol (2002) 4.65
The frequency of uterine leiomyomas. Am J Clin Pathol (1990) 4.00
Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci U S A (2001) 3.31
Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dubé syndrome. Cancer Epidemiol Biomarkers Prev (2002) 3.12
Birt-Hogg-Dubé syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. Am J Hum Genet (2001) 2.68
Cutaneous leiomyomata with uterine leiomyomata. Acta Derm Venereol (1973) 2.12
Familial cutaneous leiomyomatosis is a two-hit condition associated with renal cell cancer of characteristic histopathology. Am J Pathol (2001) 1.46
Mutation of the fumarase gene in two siblings with progressive encephalopathy and fumarase deficiency. J Clin Invest (1994) 1.45
Localization of a gene (MCUL1) for multiple cutaneous leiomyomata and uterine fibroids to chromosome 1q42.3-q43. Am J Hum Genet (2001) 1.42
Mitochondrial and cytosolic isoforms of yeast fumarase are derivatives of a single translation product and have identical amino termini. J Biol Chem (2001) 1.35
Prevalence of microscopic tumors in normal appearing renal parenchyma of patients with hereditary papillary renal cancer. J Urol (2000) 1.24
Collecting duct carcinoma of the kidney. Hum Pathol (1990) 1.17
Molecular analysis and prenatal diagnosis of human fumarase deficiency. Mol Genet Metab (1998) 1.14
Fumarase deficiency is an autosomal recessive encephalopathy affecting both the mitochondrial and the cytosolic enzymes. Neurology (1990) 1.11
Imaging features of hereditary papillary renal cancers. J Comput Assist Tomogr (1997) 1.08
Intracellular distribution of fumarase in various animals. J Biochem (1984) 1.06
Multiple leiomyomas of the esophagus, lung, and uterus in multiple endocrine neoplasia type 1. Am J Pathol (2001) 0.99
The genetic determination of fumarase isozymes in human tissues. Ann Hum Genet (1979) 0.95
Collecting duct carcinoma: cytogenetic characterization. Histopathology (1992) 0.94
High-density mapping of chromosomal arm 1q in renal collecting duct carcinoma: region of minimal deletion at 1q32.1-32.2. Cancer Res (1996) 0.92
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
Topographical and temporal diversity of the human skin microbiome. Science (2009) 15.96
High frequency of BRAF mutations in nevi. Nat Genet (2002) 9.95
STAT3 mutations in the hyper-IgE syndrome. N Engl J Med (2007) 8.99
ESUR prostate MR guidelines 2012. Eur Radiol (2012) 8.86
A diversity profile of the human skin microbiota. Genome Res (2008) 7.65
Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature (2011) 6.57
von Hippel-Lindau disease. Lancet (2003) 6.20
Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med (2006) 6.17
Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet (2011) 5.73
HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell (2005) 5.47
Phenotype and course of Hutchinson-Gilford progeria syndrome. N Engl J Med (2008) 5.34
Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell (2002) 5.23
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15
Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. Cancer Cell (2002) 5.10
The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol (2010) 5.04
An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med (2009) 4.97
Biochemical diagnosis of pheochromocytoma: which test is best? JAMA (2002) 4.84
Post-analysis follow-up and validation of microarray experiments. Nat Genet (2002) 4.61
Combined immunodeficiency associated with DOCK8 mutations. N Engl J Med (2009) 4.52
Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst (2002) 4.50
Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl J Med (2003) 4.46
The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell (2002) 4.13
Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant (2006) 4.09
Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res (2008) 4.02
Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet (2013) 3.87
Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res (2012) 3.71
Mistaken identifiers: gene name errors can be introduced inadvertently when using Excel in bioinformatics. BMC Bioinformatics (2004) 3.65
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol (2006) 3.53
Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci U S A (2006) 3.51
The genetic basis of cancer of the kidney. J Urol (2003) 3.45
Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. Am J Hum Genet (2005) 3.26
Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res (2009) 3.17
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol (2004) 3.16
Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dubé syndrome. Cancer Epidemiol Biomarkers Prev (2002) 3.12
Robotic partial nephrectomy for complex renal tumors: surgical technique. Eur Urol (2007) 3.07
Renal tumors in the Birt-Hogg-Dubé syndrome. Am J Surg Pathol (2002) 3.06
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia. Blood (2009) 3.00
Racial disparity in renal cell carcinoma patient survival according to demographic and clinical characteristics. Cancer (2012) 2.95
Can magnetic resonance-ultrasound fusion biopsy improve cancer detection in enlarged prostates? J Urol (2013) 2.81
Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N Engl J Med (2012) 2.74
High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors. J Natl Cancer Inst (2005) 2.70
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol (2012) 2.61
Correlation of magnetic resonance imaging tumor volume with histopathology. J Urol (2012) 2.55
11C-Acetate PET/CT in localized prostate cancer: a study with MRI and histopathologic correlation. J Nucl Med (2012) 2.42
Real-time MRI-TRUS fusion for guidance of targeted prostate biopsies. Comput Aided Surg (2008) 2.39
Evaluation of non-formalin tissue fixation for molecular profiling studies. Am J Pathol (2002) 2.38
Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance? Radiology (2013) 2.35
The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease. J Neurosurg (2003) 2.34
Characteristics of congenital hepatic fibrosis in a large cohort of patients with autosomal recessive polycystic kidney disease. Gastroenterology (2012) 2.33
Evaluation and management of renal tumors in the Birt-Hogg-Dubé syndrome. J Urol (2005) 2.33
The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. J Urol (2004) 2.32
The Ter mutation in the dead end gene causes germ cell loss and testicular germ cell tumours. Nature (2005) 2.29
Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. Proc Natl Acad Sci U S A (2009) 2.28